NCT02244333View on ClinicalTrials.gov

Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)

CompletedOBSERVATIONAL
Enrollment

4,575

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

July 31, 2004

Conditions
Prostatic Hyperplasia
Interventions
DRUG

ALNA®

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY